Immunity to fungi and vaccine considerations
Authors:
- 9 October 2024
- journal article
- review article
- Published by Elsevier in Cell Host & Microbe
- Vol. 32 (10) , 1681-1690
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institute for Advanced Research
- Hartwell Foundation
- National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases
- National Science Foundation Directorate for Biological Sciences
This publication has 133 references indexed in Scilit:
- The immunostimulatory nature of mRNA lipid nanoparticlesAdvanced Drug Delivery Reviews, 2024
- Enolase 1 of Candida albicans binds human CD4+ T cells and modulates naïve and memory responsesEuropean Journal of Immunology, 2023
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and RezafunginDrugs, 2021
- COVID-19-associated opportunistic infections: a snapshot on the current reportsClinical and Experimental Medicine, 2021
- Pharmaceutical strategies to extend pulmonary exposure of inhaled medicinesActa Pharmaceutica Sinica B, 2021
- Commensal Candida albicans Positively Calibrates Systemic Th17 Immunological ResponsesCell Host & Microbe, 2019
- Phagocytosis Dynamics Depends on Target ShapeBiophysical Journal, 2013
- Trained Immunity: A Memory for Innate Host DefenseCell Host & Microbe, 2011
- New humanized HLA–DR4–transgenic mice that mimic the sex bias of rheumatoid arthritisArthritis & Rheumatism, 2007
- The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic stem cell transplantationCancer, 2005